In An Organic Compound Patents (Class 424/1.65)
  • Patent number: 10406246
    Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof having a chemical structure comprising: (A) at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; and (C) at least one dye moiety; wherein said compound has a molecular weight of not more than 5 kDa. Further, the invention refers to a method for producing such compound and to the in vivo and in vitro uses thereof.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: September 10, 2019
    Assignee: Deutsches Kresbsforschungszentrum
    Inventors: Matthias Eder, Klaus Kopka, Martin Schaefer, Ulrike Bauder-Wuest, Uwe Haberkorn
  • Patent number: 10398791
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 3, 2019
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Uwe Haberkorn, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 10377778
    Abstract: The present invention relates complexes comprising a PSMA targeting compound linked to a radionuclide, such as 212Pb or 227Th. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 13, 2019
    Assignee: Sciencons AS
    Inventor: Roy Hartvig Larsen
  • Patent number: 10303846
    Abstract: A method of analyzing biological data containing expression values of a plurality of polypeptides in the blood of a subject. The method comprises: calculating a distance between a segment of a curved line and an axis defined by a direction, the distance being calculated at a point over the curved line defined by a coordinate along the direction. The method further comprises correlating the distance to the presence of, absence of, or likelihood that the subject has, a bacterial infection. The coordinate is defined by a combination of the expression values, wherein at least 90% of the segment is between a lower bound line and an upper bound line.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: May 28, 2019
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Eran Eden, Kfir Oved, Roy Navon, Assaf Cohen-Dotan, Olga Boico
  • Patent number: 10278657
    Abstract: A method for performing an imaging scan of a subject includes positioning a narrow field-of-view camera at a first imaging position to acquire a first set of imaging information of a first object of interest, positioning the narrow field-of-view camera at a second imaging position to acquire a second set of imaging information of a second object of interest, determining emission counts for the first and second sets of imaging information, and utilizing the determined emission counts to generate a value that indicates a probability of a successful medical procedure being performed on the subject.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: May 7, 2019
    Assignee: General Electric Company
    Inventors: Aharon Peretz, Yaron Hefetz, Lana Volokh
  • Patent number: 10233277
    Abstract: Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: March 19, 2019
    Assignee: The Governing Council of the University of Toronto
    Inventors: Xiao Yu Wu, Alireza Shalviri, Ping Cai
  • Patent number: 10150804
    Abstract: Somatostatin derivative compounds of general formula (I) that may be readily labelled with the isotope fluorine-18 and that have affinity and selectivity for cellular somatostatin receptors are provided. The labelled compounds are useful clinically as radioactive tracers in various in vivo imaging applications (for example, using positron emission tomography (PET) and related techniques) to detect somatostatin-expressing cells and tissues, including tumors, or as therapeutic agents.
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: December 11, 2018
    Inventors: Francois Benard, Kuo-Shyan Lin, David Perrin, Zhibo Liu, Maral Pourghiasian
  • Patent number: 10071943
    Abstract: Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disclosed.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 11, 2018
    Inventors: Peter J. H. Scott, Melanie S. Sanford, Naoko Ichiishi, Allen F. Brooks, Melissa Rodnick, Joseph J. Topczewski
  • Patent number: 10040854
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human endothelial vascular cell adhesion molecule-1 (VCAM-1), wherein the antibody or fragment thereof binds to the extracellular domain of VCAM-1, and wherein the antibody or fragment thereof binds to VCAM-1 when expressed on endothelial cells, wherein the antibody or fragment thereof is a human or humanized antibody, or fragment thereof.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: August 7, 2018
    Inventors: Daniel Clive Anthony, Sandra Jane Campbell, Francis Joseph Carr, Robin Patrick Choudhury, Benjamin Guy Davis, Timothy David Jones, Nicola Ruth Sibson
  • Patent number: 9999693
    Abstract: Disclosed herein are globular nanostructures having a hydrodynamic diameter (Dh) of 8-100 nm comprising a central part and a peripheral part, wherein said central part has a calculated diameter (Dc) of 6-90 nm and said peripheral part has an estimated thickness (Tp) so that Dh=Dc+2Tp, wherein said central part comprises: (i) a crosslinked polymeric framework comprising monomer residues wherein at least 30% by number of the monomer residues have crosslinked thereby forming the crosslinked polymeric framework and/or (ii) a branched polymeric framework comprising monomer residues wherein the number of branch points is at least 30% of the number of monomer residues, wherein said central part comprises chelating groups of which at least 4 allow chelation of at least one multiply charged cation, wherein said chelating groups are independently selected from the group consisting of —COOR1, —P?O(OR1)(OR2), and —S(?O)2OR1, wherein R1 and R2 are independently selected from the group consisting of a negative charge, H, a
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 19, 2018
    Inventors: Oskar Axelsson, Sania Bäckström, Rodrigo Petoral, Jr.
  • Patent number: 9993439
    Abstract: The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: June 12, 2018
    Inventors: Frank X. Gu, Lyndon William James Jones, Shengyan (Sandy) Liu
  • Patent number: 9932369
    Abstract: The present invention relates to a biopolymer and a cell-harvesting scaffold comprising same, as well as the associated cell-harvesting method that allows said harvesting to be performed in a simple and effective manner by reducing the culture temperature. The present invention also relates to a method for synthesizing said biopolymer.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 3, 2018
    Inventors: Jose Carlos Rodriguez-Cabello, Francisco Javier Arias Vallejo, Matilde Alonso Rodrigo, Mercedes Santos Garcia, Maria Pierna Alvarez
  • Patent number: 9919059
    Abstract: Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: March 20, 2018
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Cliff R. Wong, Moungi G. Bawendi, Dai Fukumura, Rakesh K. Jain
  • Patent number: 9850183
    Abstract: Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: December 26, 2017
    Assignee: Reiley Pharmaceuticals, Inc.
    Inventors: Mark A. Reiley, B. Michael Silber, Julio Medina, Frank Kayser, William D. Shrader
  • Patent number: 9822134
    Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 21, 2017
    Assignee: SABAG-RFA LTD.
    Inventor: David Segev
  • Patent number: 9805224
    Abstract: A magnetic anti-counterfeit label and identification system thereof, wherein the magnetic anti-counterfeit label comprises a substrate, a magnetic ink layer, an opaque layer and a protective coating. The magnetic ink layer covers the substrate. The opaque layer covers the magnetic ink layer in order to visually hide the characters, bar code, and other patterns which are printed using magnetic ink. Additionally the protective coating is composed of a polymer or a metal layer, which covers opaque layer. This identification system comprises a magnetic sensor for sensing the magnitude of the magnetic field emitted by the magnetic anti-counterfeit label, a permanent magnet or an electromagnet for magnetizing the magnetic anti-counterfeit label, a digital processing circuit that is electrically connected to the magnetic sensor, and a frame that is used to hold the magnetic sensor and the digital processing circuit. The digital processing circuit outputs a code corresponding to the magnetic anti-counterfeit label.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 31, 2017
    Assignee: MultiDimension Technology Co., Ltd.
    Inventors: James Geza Deak, Xiaofeng Cheng
  • Patent number: 9776977
    Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 3, 2017
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray
  • Patent number: 9724434
    Abstract: There is provided a lysine oligomer derivative, wherein an ?-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an ?-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 8, 2017
    Inventors: Toshitaka Oohashi, Hiroki Kakuta
  • Patent number: 9701694
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: July 11, 2017
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Patent number: 9687635
    Abstract: For selective treatment of diseased tissue sections or organ parts, the surface of medical devices entering into contact with areas thereof under pressure is coated with lipophilic substantially water-insoluble medicaments binding to various tissue components with good adherence thereto, said medicaments having an effect thereupon a short time after entering into contact therewith without exerting a harmful influence upon adjacent healthy tissue.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 27, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Speck, Bruno Scheller
  • Patent number: 9663565
    Abstract: The present invention relates to an insulinotropic peptide derivative with a modified N-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the N-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is rapidly dissociated from the GLP-1 receptor owing to the above modification in the N-terminal charge, and exhibits enhanced insulinotropic ability and blood glucose-lowering activity compared to the native insulinotropic peptide while maintaining its stability in blood. Accordingly, the insulinotropic peptide derivative of the present invention is very useful for the treatment of type 2 diabetes.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: May 30, 2017
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Sung Youb Jung, Sang Youn Hwang, In Young Choi, Sung Hee Park, Se Chang Kwon
  • Patent number: 9629923
    Abstract: A CDDP complex is formed by complexation of CDDP and a polymer having a structure of Formula (I). The CDDP complex has good biocompatibility and is degradable. A side chain of the polymer is grafted with polyethylene glycol, which gives the CDDP complex good dissolvability. When dissolved in an aqueous medium, the CDDP is protected by a hydrophilic polyethylene glycol chain segment and a hydrophobic amino acid chain segment, which can effectively avoid a sudden release of the CDDP due to the influence of the blood circulation system after intravenous injection, thus improving the stability of the CDDP complex. A carboxyl group contained in the CDDP complex has pH value sensitivity and tends to be deprotonated in a low pH environment, which is advantageous for promoting the release of a drug, and improving the efficiency of the drug.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: April 25, 2017
    Assignee: Changchun Institute of Applied Chemistry, Chinese Academy of Science
    Inventors: Zhaohui Tang, Haiyang Yu, Wantong Song, Mingqiang Li, Xiuli Zuang, Xuesi Chen
  • Patent number: 9585976
    Abstract: The present invention provides an automated method for the preparation of 123I-labelled radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation of 123I-labelled radiopharmaceuticals is also described. Also described is the use of cassettes of the present invention in the preparation of 123I-labelled radiopharmaceuticals.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: March 7, 2017
    Assignee: GE Healthcare Limited
    Inventors: Nigel Anthony Powell, Brian Higley, Roger Paul Pettitt
  • Patent number: 9498545
    Abstract: A nanosensor-containing polymer composition for the monitoring of physiological parameters and a method for making the composition are disclosed. The composition includes a fluid nanosensor-containing polymer that becomes rigid in the presence of physiological conditions. In the fluid form, the composition can be suitable for injection on to or into the skin. In the rigid form, the nanosensor is substantially immobilized in the polymer. The method includes forming a mixture comprising a nanosensor and polymer precursor(s), subjecting the mixture to conditions suitable for forming the fluid form of the composition; and subjecting the fluid form to physiological conditions to provide a rigid nanosensor-containing composition.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: November 22, 2016
    Assignee: Verily Life Sciences LLC
    Inventors: Kimberly Kam, Jerrod Joseph Schwartz
  • Patent number: 9486508
    Abstract: The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: November 8, 2016
    Inventors: Gregory M. Lanza, Dipanjan Pan, Allan Doctor, Philip C. Spinella
  • Patent number: 9447122
    Abstract: The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: September 20, 2016
    Assignee: AstraZeneca AB
    Inventors: Bruce Edward Tomczuk, Gary Lee Olson, Richard Scott Pottorf, Lijuan Jane Wang, Bhaskara Rao Nallaganchu, Yanqun Zhang
  • Patent number: 9433594
    Abstract: A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 6, 2016
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
  • Patent number: 9422251
    Abstract: A ligand, a pharmaceutically acceptable salt, tautomer, or ester thereof, may be represented as: In the formula, X is selected from the group consisting of —(CH2)n—, —(CH2)n—O—, —(CH2)n—N(Rg)—, —(CH2)n—N(Rg)—C(O)— and —O—; Rg is hydrogen or (C1-C6)alkyl; G is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; G? is —(CH(Rm))n—Rh—, or —(CH2)p—C(O)—Rh; Rh is —H, —OH, NRaRb, or —CO2H; Rm is —H, —COOH, or substituted or unsubstituted —COO(C1-C6)alkyl; Ra and Rb are each independently H, substituted or unsubstituted (C1-C8)alkyl, or substituted or unsubstituted carboxy(C1-C8)alkylene; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and p is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: August 23, 2016
    Assignee: Molecular Insight Pharmaceuticals, Inc.
    Inventors: John W. Babich, Craig Zimmerman, John L. Joyal, Genliang Lu, Shawn Hillier, Kevin P. Maresca, John Marquis
  • Patent number: 9346832
    Abstract: The invention provides compounds of the Formula (I), in which W is independently selected from W1, W2, W3, W4, W5, or W represents a pair of substituents independently selected from H, alkyl, aryl or amide in which the amide is optionally part of a linking chain, and the Zn—Zn? bonds (n=4-17; n?=n+1) are optionally of any whole or partial bond order, Y is Y1 or Y represents a pair of substituents independently selected from H, C1-C6 alkyl, Z5 or Z6 aryl, or Y is optionally a bridging structure that may comprise one or more C1-C6 amide, C1-C6 ether, or C1-C6 ester groups, R—R39 are independently selected from no substituent, a lone pair of electrons, H, halogen, C5-C6 aryl, C1-C12 alkyl, amine, C1-C6 alkylamine, C1-C6 amide, nitro, cyano, carboxyl, C1-C6 ester, phosphane, thiol, C1-C6 thioether, OR40, and suitable pairs of adjacent R groups (R—R39) may optionally together form part of a C5 or C6 aryl ring, a Z5 or Z6 ring, R40 is independently selected from H, C1-C6 alkyl, Z5 or Z6 ar
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: May 24, 2016
    Assignee: University of Kwazulu-Natal
    Inventors: Orde Quentin Munro, Kate Julie Akerman, Piers Akerman
  • Patent number: 9259496
    Abstract: The present invention relates to technetium imaging agents comprising radiolabeled c-Met binding peptides suitable for SPECT or PET imaging in vivo. The c-Met binding peptides are labelled via chelator conjugates. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the diagnosis of cancer.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: February 16, 2016
    Assignee: GE Healthcare Limited
    Inventors: Peter Brian Iveson, Bard Indrevoll, Ben Newton, Rajiv Bhalla, Edvin Wilhelm Johannesen
  • Patent number: 9233178
    Abstract: Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: January 12, 2016
    Inventors: Martin G. Pomper, Haofan Wang, Tomas R. Guilarte
  • Patent number: 9205156
    Abstract: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: December 8, 2015
    Inventors: Eyal Mishani, Ohad Ilovich, Hana Billauer, Sharon Dotan, Haim Danenberg, Moshe Bocher, Galith Abourbeh, Nanette Freedman
  • Patent number: 9186644
    Abstract: A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of 62Cu-labeled radiopharmaceuticals (62Cu-ligand) can be interchangeably synthesized with only one 62Zn/62Cu generator.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: November 17, 2015
    Assignee: Proportional Technologies, Inc.
    Inventor: Jeffrey L. Lacy
  • Patent number: 9125942
    Abstract: The present invention provides compositions and methods for the synthesis of conjugates of paramagnetic metal ions and nanodiamonds, and uses thereof. In particular, the present invention provides synthesis of paramagnetic metal-nanodiamond conjugates and methods using such compositions as molecular imaging probes.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: September 8, 2015
    Inventors: Lisa M. Manus, Daniel J. Mastarone, Dean Ho, Thomas J. Meade
  • Patent number: 9120837
    Abstract: The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E? and G are as defined above. Also described are Pt, 64Cu, 186Re, 188Re and 99mTc metal complexes of Formula I compounds which find use as candidate agents for imaging tumors.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 1, 2015
    Inventors: John W. Babich, Craig Zimmerman, John L. Joyal, Genliang Lu, Shawn Hillier, Kevin P. Maresca, John Marquis
  • Patent number: 9101672
    Abstract: Disclosed herein is the novel use of a gold nanocluser for ameliorating oxidative stress and/or aging of a cultured cell or a subject having an oxidative stress and/or aging condition mediated by a vascular factor. The gold nanocluster has a particle size ranging from about 0.1 to 20 nm, and preferably is dihydrolipoic acid (DHLA) coated gold nanocluster.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: August 11, 2015
    Inventors: Hung-I Yeh, Walter H. Chang, Cheng-An Lin, Hsueh-Hsiao Wang
  • Patent number: 9061077
    Abstract: This disclosure relates to the methods of imaging the kidneys and measuring renal function using the renal tracer 99mTc(CO)3(NTA) (technetium-99m tricarbonyl-nitrilotriacetic acid). The disclosure encompasses methods of imaging the kidneys and measuring effective renal plasma flow (ERPF) in an animal or human subject using renal scintigraphy, comprising administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99mTc-(CO)3(NTA). Another aspect of the disclosure are methods of measuring effective renal plasma flow in an animal or human subject, comprising administering to an animal or human subject an amount of a renal tracer, wherein the renal tracer comprises 99mTc-(CO)3(NTA), isolating a series of plasma samples from the animal or human subject after administering the renal tracer and quantitatively detecting the amount of the renal tracer in the biological samples.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: June 23, 2015
    Assignee: Emory University
    Inventors: Malgorzata Lipowska, Andrew T. Taylor, Jr., Luigi Marzilli
  • Publication number: 20150148256
    Abstract: A bioluminescence imaging-based high-throughput assay for inhibitors of ABCG2 is described. Compositions of inhibitors of ABCG2 and methods of using ABCG2 inhibitors are also described.
    Type: Application
    Filed: August 21, 2014
    Publication date: May 28, 2015
  • Publication number: 20150147272
    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyi solubilising group and wherein the tissue targeting moiety has binding affinity for the CD33 receptor. A corresponding pharmaceutical formulation and method and use in treatment, as well as methods of manufacture are provided.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 28, 2015
    Inventors: Hanne Therese Bonge-Hanssen, Olav Benjamin Ryan
  • Patent number: 9040019
    Abstract: A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 26, 2015
    Assignee: General Electric Company
    Inventors: Tiberiu Mircea Siclovan, Cristina Abucay Tan Hehir, Rong Zhang, Victoria Eugenia Cotero, Anshika Bajaj
  • Publication number: 20150139901
    Abstract: The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Applicants: Institut National de la Sante et de la Recherche (INSERM), Chu Nantes, Universite de Nantes, Centre National de la Recherche Scientifique (C.N.R.S.), Universite d' Angers
    Inventors: Alain Faivre-Chauvet, Holisoa Rajaerison, Jean-Francois Gestin
  • Patent number: 9034298
    Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: May 19, 2015
    Assignee: Koninklijke Philips N.V.
    Inventors: Holger Gruell, Anke De Vries, Sander Langereis, Johan Lub, Erica M. G. Aussems-Custers
  • Patent number: 9028799
    Abstract: A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: May 12, 2015
    Inventor: Jianping Ruan
  • Patent number: 9028800
    Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: May 12, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
  • Patent number: 9028802
    Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 12, 2015
    Assignee: Koninklijke Philips N.V.
    Inventor: Frank Olaf Thiele
  • Publication number: 20150125388
    Abstract: The invention relates to novel multi-modality probes for imaging, tracking and analyzing stem cells and related biological samples, and methods of preparation and use thereof. The molecular probes of the invention are constructed, for example, by utilizing (a) the high selectivity of long hydrocarbon chains for binding to plasma membranes of cells, (b) a near-infrared (NIR) dye for optical imaging, and (c) a radionuclide for PET or SPECT imaging. The in vitro and in vivo data of the optical and radiolabeled probes demonstrated their utility for detecting the presence of stem cells with multiple imaging modalities.
    Type: Application
    Filed: May 27, 2013
    Publication date: May 7, 2015
    Applicant: Vniversity of Massachusetts Medical School
    Inventors: Brian D. Gray, Mary Rusckowski, Koon Y. Pak
  • Patent number: 9023315
    Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: May 5, 2015
    Assignee: Mallinckrodt LLC
    Inventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
  • Patent number: 9023317
    Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: May 5, 2015
    Assignee: University of Western Ontario
    Inventors: Duncan H. Hunter, Mustafa Janabi
  • Publication number: 20150118156
    Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 30, 2015
    Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
  • Patent number: 9017644
    Abstract: The present invention relates to dendrimer compositions configured for treating inflammatory disorders and autoimmune disorders, and related methods of synthesis. Specifically, the present invention relates to methods for treating rheumatoid arthritis with PAMAM dendrimers having functional ligands configured for treating rheumatoid arthritis (e.g., therapeutic agents, pro-drugs, targeting agents, trigger agents, imaging agents) (e.g., methotrexate).
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: April 28, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Larry A. Sternson, David Repp, Deborah Ladenheim